Insider · SEC Form 4 filer
Fairmount Healthcare Fund II L.P.
Companies
Where they file as an insider
Apogee Therapeutics (APGE) Director Latest filing Aug 7, 2026
Crescent Biopharma (CBIO) Director, 10% owner Latest filing Jul 16, 2026
Viridian Therapeutics (VRDN) Director, 10% owner Latest filing May 11, 2026
Galecto (GLTO) 10% owner Latest filing Feb 9, 2026
Jade Biosciences (JBIO) Director, 10% owner Latest filing Oct 6, 2025
Spyre Therapeutics (SYRE) Director, 10% owner Latest filing Dec 29, 2023
Track record
Did their buys beat the typical stock?
Open-market buys4
Quarters checked 6 months later2
Beat the typical stock —
Quarters too new to check2
Too soon to tell. 2 quarters have finished so far. We show a record once 3 have.
Crescent Biopharma (CBIO) Bought Jul 16, 2026 · $12.4M · 853,450 shares Too new Too new. Its 6-month check uses prices as of Mar 31, 2027.
Viridian Therapeutics (VRDN) Bought May 11, 2026 · $20M · 1.18M shares Too new Too new. Its 6-month check uses prices as of Dec 31, 2026.
Viridian Therapeutics (VRDN) Bought Sep 13, 2024 · $30M · 1.6M shares Behind typical Sep 30, 2024 $22.75 → Mar 31, 2025 $13.48 · −40.7% (typical stock −7.5%)
Viridian Therapeutics (VRDN) Bought Jan 22, 2024 · $10M · 476,190 shares Beat typical Mar 31, 2024 $17.51 → Sep 30, 2024 $22.75 · +29.9% (typical stock +3.2%)
Each row is one stock in one quarter, however many buys it took. We take the stock's price at the end of that quarter and again 6 months later, and compare it with the typical stock over the same dates. Prices are quarter-end values from funds' 13F reports (the middle value across 3 or more funds), through Sep 30, 2026. Moves past 3 times up or down, mostly stock splits, are left out. How we tested this.
Past results. This is data, not advice.
Free weekly email
Each week's biggest real insider buys, cluster buys and fund moves, every one dated. One email a week. Unsubscribe in one click.